Related Experiment Video
Updated: Jun 25, 2026
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
Published on: June 18, 2013
Tumor targeting using canine parvovirus nanoparticles
1Division of Hematology and Oncology, Department of Medicine, Building 23, Room 436A, UCI Medical Center, 101 City Drive South, Orange, CA 92868, USA. pratiks@uci.edu
Abstract:
Advances in genetics, proteomics and cellular and molecular biology are being integrated and translated to develop effective methods for the prevention and control of cancer. One such combined effort is to create multifunctional nanodevices that will specifically recognize tumors and thus enable early diagnosis and provide targeted treatment of this disease. Viral particles are being considered for this purpose since they are inherently nanostructures with well-defined geometry and uniformity, ideal for displaying molecules in a precise spatial distribution at the nanoscale level and subject to greater structural control. Viruses are presumably the most efficient nanocontainer for cellular delivery as they have naturally evolved mechanisms for binding to and entering cells. Virus-based systems typically require genetic or chemical modification of their surfaces to achieve tumor-specific interactions. Interestingly, canine parvovirus (CPV) has a natural affinity for transferrin receptors (TfRs) (both of canine and human origin) and this property could be harnessed as TfRs are overexpressed by a variety of human tumor cells. Since TfR recognition relies on the CPV capsid protein, we envisioned the use of virus or its shells as tumor targeting agents. We observed that derivatization of CPV virus-like particles (VLPs) with dye molecules did not impair particle binding to TfRs or internalization into human tumor cells. Thus CPV-based VLPs with a natural tropism for TfRs hold great promise in the development of novel nanomaterial for delivery of a therapeutic and/or genetic cargo.
Insights
Canine parvovirus (CPV) virus-like particles (VLPs) show promise for cancer treatment. These CPV-based VLPs naturally target tumor cells by binding to transferrin receptors (TfRs), enabling potential early diagnosis and targeted therapy.
Area of Science:
- Oncology
- Nanotechnology
- Virology
Background:
- Cancer research integrates genetics, proteomics, and molecular biology for novel prevention and control strategies.
- Multifunctional nanodevices are being developed for early cancer diagnosis and targeted treatment.
- Viral particles offer unique advantages as nanostructures for targeted delivery due to their natural cell-binding and entry mechanisms.
Purpose of the Study:
- To investigate the potential of canine parvovirus (CPV) and its virus-like particles (VLPs) as tumor-targeting agents.
- To leverage the natural affinity of CPV for transferrin receptors (TfRs), which are overexpressed on human tumor cells.
- To explore the feasibility of using CPV-based VLPs for targeted delivery of therapeutic or genetic cargo.
Main Methods:
- Utilized canine parvovirus (CPV) virus-like particles (VLPs) as a base nanostructure.
- Investigated the natural tropism of CPV VLPs for transferrin receptors (TfRs).
- Modified CPV VLPs with dye molecules to assess impact on TfR binding and cellular internalization.
Main Results:
- CPV VLPs demonstrated natural binding affinity to transferrin receptors (TfRs) of both canine and human origin.
- Derivatization of CPV VLPs with dye molecules did not impede their ability to bind to TfRs.
- Modified CPV VLPs were successfully internalized into human tumor cells, confirming their targeting capability.
Conclusions:
- CPV-based VLPs possess inherent tumor-targeting capabilities due to their natural tropism for TfRs.
- These CPV-derived nanostructures are promising for the development of novel nanomaterials for cancer therapy and diagnosis.
- Further development of CPV-based VLPs could lead to advanced targeted drug or gene delivery systems for cancer treatment.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...